Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Artificial ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody ...

Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface of B cells, which has established benefit in RA both with regards to clinical efficacy and ...